Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: Results of the FINEST study

European Journal of Radiology

Volumn 73, Issue 2, 2010, Pages 357-359

  Janus, Nicolas ^a   Launay Vacher, Vincent ^a   Karie, Svetlana ^a   Clement, Olivier ^b   Ledneva, Elena ^a   Frances, Camille ^c   Choukroun, Gabriel ^d   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c HÔPITAL TENON   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Gadolinium chelate; MRI examination; Nephrognic systemic fibrosis

Indexed keywords

GLOMERULAR FILTRATION RATE; MACROCYCLICS; MEAN AGES; NEPHROGENIC SYSTEMIC FIBROSIS; RARE DISEASE; RENAL FUNCTIONS; SKIN BIOPSIES;

CHELATION; MAGNETIC RESONANCE IMAGING; NEON; OPTICAL DEVICES; RESONANCE;

GADOLINIUM;

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE;

ADULT; AGED; ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DISEASE;

COMORBIDITY; FEMALE; FRANCE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PREVALENCE; RENAL INSUFFICIENCY; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 76349121764     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.11.021     Document Type: Article

References (20)

1. Cowper S.E., Robin H.S., Steinberg S.M., Su L.D., Gupta S., and LeBoit P.E. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 (2000) 1000-1001
2. Broome D.R. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66 (2008) 230-234
3. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
4. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359-2362
5. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67 (2005) 2089-2100
6. Rydahl C., Thomsen H.S., and Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 43 (2008) 141-144
7. Todd D.J., Kagan A., Chibnik L.B., and Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56 (2007) 3433-3441
8. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 (2007) 148-157
9. Kanal E., Broome D.R., Martin D.R., and Thomsen H.S. Response to the FDA's May 23, 2007 nephrogenic systemic fibrosis update. Radiology 246 (2008) 11-14
10. Perazella M.A. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link?. Clin J Am Soc Nephrol 2 (2007) 200-202
11. Idee J.M., Port M., Raynal I., Schaefer M., Le Greneur S., and Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20 (2006) 563-576
12. Laurent S., Elst L.V., and Muller R.N. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 1 (2006) 128-137
13. Thomsen H.S., Morcos S.K., and Dawson P. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?. Clin Radiol 61 (2006) 905-906
14. Chewning R.H., and Murphy K.J. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency. J Vasc Interv Radiol 18 (2007) 331-333
15. Lin S.P., and Brown J.J. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 25 (2007) 884-899
16. Thomsen H.S. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 17 (2007) 70-76
17. Morcos S.K. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?. Br J Radiol 80 (2007) 73-76
18. Solomon R., and Deray G. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl (2006) S51-S53
19. McCullough P.A., and Sandberg K.R. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 4 Suppl. 5 (2003) S3-S9
20. Mehran R., and Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl (2006) S11-S15